Valuation — not yet established
No valuation for Inhibrx is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($255.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Inhibrx
Create free account
No card required
Funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Aug 2023 | PIPE | $200.0M | ▮ | ▮ |
| Apr 2020 | Later Stage VC | $55.0M | ▮ | ▮ |
| May 2019 | Early Stage VC | $40.0M | ▮ | ▮ |
| May 2018 | Seed Round | $3.5M | ▮ | ▮ |
How Inhibrx's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Inhibrx, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Inhibrx raised?
- Inhibrx has raised $255.0M in total funding across 4 recorded rounds.
- When did Inhibrx last raise?
- Inhibrx last raised in Aug 2023 (PIPE), raising $200.0M.